Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
1
A protein subunit vaccine for control of Asian long-horned ticks in cattle
Award last edited on: 1/29/2024
Sponsored Program
SBIR
Awarding Agency
USDA
Total Award Amount
$128,986
Award Phase
1
Solicitation Topic Code
8.3
Principal Investigator
Casey Wright
Company Information
VST LLC
101 N Main Avenue
Sioux Falls, SD 57104
(605) 929-8942
N/A
www.medgenelabs.com
Location:
Single
Congr. District:
00
County:
Minnehaha
Phase I
Contract Number:
2023-01424
Start Date:
4/5/2023
Completed:
2/29/2024
Phase I year
2023
Phase I Amount
$128,986
Tick-borne pathogens cause major economic losses to the livestock industry leading to an estimated $19.7 billion in losses for the U.S. including approximately $3 billion in losses for cattle producers. Among the 900 species of ticks the Asian long horned tick (ALT) an invasive non- native tick species poses a major threat to animal health and productivity in cattle and other livestock. Currently tick management includes inspection and chemical control and can be a tedious and expensive process for livestock producers. Unfortunately there are no vaccines in the U.S. that target ALT. Medgene Labs will develop the first U.S.-based ALT anti-tick vaccine which will be baculovirus derived and administered as a 1- or 2-dose regimen. This vaccine will significantly reduce the cost time and effort associated with herd management. This Phase I project will 1) develop a vaccine that targets ALT infestations and 2) assess the immunogenicity of the vaccine in cattle through serological assays. Successful completion of our Phase I project will generate critical proof-of-concept data to support larger vaccine study trials in Phase II to establish the utility of our vaccine against tick-borne disease in cattle and will provide a model for the development of effective vaccines against other tick species native to the U.S. Anticipated Phase II work will lead to submission of an Investigational New Animal Drug Application to the FDA's Center for Veterinary Medicine and enable the rapid deployment of an ALT vaccine to prevent tick-borne illness.
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.